Publications by authors named "Owen A Ledwell"
The Bi-Steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol
November 2024
Article Synopsis
- * The only approved treatment, Rapamycin, offers limited benefits as lung function declines after stopping the drug, with LAM cancer stem-like cells displaying high levels of cancer-promoting protein synthesis.
- * A new compound, RMC-5552, shows promise by effectively inhibiting LAM-associated cell growth and providing longer-lasting effects than Rapamycin, suggesting it could be a potential therapy for LAM and other conditions with mTORC1 hyperactivity.
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease caused by tuberous sclerosis complex 1/2 (TSC1/2) gene mutations in pulmonary mesenchymal cells, resulting in activation of the mechanistic target of rapamycin complex 1 (mTORC1). A subset of patients with LAM develop pulmonary vascular remodeling and pulmonary hypertension. Little, however, is known regarding how LAM cells communicate with endothelial cells (ECs) to trigger vascular remodeling.
View Article and Find Full Text PDF